Cagrilintide Research Guide: Long-Acting Amylin Analog

<p>Cagrilintide is a long-acting amylin analog developed by Novo Nordisk, designed to activate the amylin receptor system with an extended pharmacokinetic profile. Amylin (islet amyloid polypeptide, IAPP) is a peptide co-secreted with insulin from pancreatic beta cells and acts as a satiety hormone through calcitonin receptor/RAMP complexes in the CNS, particularly in the area postrema.</p><h2>Molecular Profile</h2><p>Cagrilintide is a synthetic amylin analog with extended fatty acid modification enabling once-weekly dosing. MW: approximately 3.4 kDa.</p><h2>Amylin Receptor Mechanism</h2><p>Amylin receptors are heteromeric complexes of the calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3). These complexes are expressed prominently in the area postrema — a circumventricular organ with direct access to blood-borne peptides — and in the hypothalamic arcuate nucleus. Amylin receptor activation reduces food intake, slows gastric emptying, and suppresses glucagon release in animal models.</p><h2>CagriSema Combination Research</h2><p>Cagrilintide has been investigated most extensively in combination with GLP-1 (S) (the combination termed 'CagriSema'). Published Phase 2 data in the NEJM demonstrated substantial effects on body weight outcomes in a clinical study population, informing the Phase 3 REDEFINE program. This combination research context makes cagrilintide increasingly relevant to researchers studying complementary incretin/amylin pathway interactions.</p><p>↗ Lau DCW et al. (2023). Weekly cagrilintide (2.4 mg) plus GLP-1 (S) (2.4 mg) in adults with overweight and obesity. Lancet. DOI: 10.1016/S0140-6736(23)01800-X</p><h2>Research Applications</h2><ul><li>Amylin receptor (CTR/RAMP) pharmacology studies</li><li>Satiety pathway and gut-brain axis research</li><li>Gastric motility pathway research in animal models</li><li>Combination studies with GLP-1R agonists (GLP-1 (S))</li><li>Glucagon suppression pathway research</li></ul><p>Q: How does cagrilintide differ from native amylin?</p><p>A: Cagrilintide incorporates structural modifications and a fatty acid side chain that dramatically extend half-life (to approximately once-weekly dosing) compared to native amylin, which has a half-life of minutes.</p><p>Q: What is the CagriSema combination?</p><p>A: CagriSema is the co-administration of cagrilintide + GLP-1 (S), studied as complementary amylin + GLP-1R pathway engagement. Phase 3 data is pending.</p><p>Related: Cagrilintide Product → | GLP-1 (S) Research Guide → | TZ2 – GLP2 Research Guide → | RT3 – GLP3 Research Guide →</p>